SCH 2047069, a novel oral kinesin spindle protein inhibitor, shows single-agent antitumor activity and enhances the efficacy of chemotherapeutics

Molecular Cancer Therapeutics

Volumn 9, Issue 11, 2010, Pages 2993-3002

  Basso, Andrea D ^a   Liu, Ming ^a   Dai, Chaoyang ^a   Gray, Kimberly ^a   Nale, Lissette ^a   Tevar, Seema ^a   Lee, Suining ^a   Liang, Lianzhu ^a   Ponery, Abdul ^a   Yaremko, Bohdan ^a   Smith, Elizabeth ^a   Tang, Huadong ^a   Sheth, Payal R ^a   Siddiqui, M Arshad ^a   Hicklin, Daniel J ^a   Kirschmeier, Paul ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; HISTONE H3; KINESIN; KINESIN SPINDLE PROTEIN; PACLITAXEL; PROTEIN INHIBITOR; SCH 2047069; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DOG; DRUG PENETRATION; DRUG POTENTIATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MITOSIS INHIBITION; MONKEY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; BENZOPYRANS; DOGS; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HAPLORHINI; HCT116 CELLS; HUMANS; KINESIN; MICE; MICE, NUDE; NEOPLASMS; RATS; THIADIAZOLES; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 78649645483     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0548     Document Type: Article

References (17)

1. Kapoor TM, Mitchison TJ. Eg5 is static in bipolar spindles relative to tubulin: evidence for a static spindle matrix. J Cell Biol 2001;154:1125-33.
2. Krzysiak TC, Grabe M, Gilbert SP. Getting in sync with dimeric Eg5. Initiation and regulation of the processive run. J Biol Chem 2008;283:2078-87.
3. Mountain V, Simerly C, Howard L, Ando A, Schatten G, Compton DA. The kinesin-related protein, HSET, opposes the activity of Eg5 and cross-links microtubules in the mammalian mitotic spindle. J Cell Biol 1999;147:351-66. (Pubitemid 29496343)
4. Gaglio T, Saredi A, Bingham JB, et al. Opposing motor activities are required for the organization of the mammalian mitotic spindle pole. J Cell Biol 1996;135:399-414. (Pubitemid 26359334)
5. Blangy A, Lane HA, d'Herin P, Harper M, Kress M, Nigg EA. Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell 1995;83:1159-69.
6. Kapoor TM, Mayer TU, Coughlin ML, Mitchison TJ. Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, Eg5. J Cell Biol 2000;150:975-88.
7. Tao W, South VJ, Zhang Y, et al. Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage. Cancer Cell 2005;8:49-59.
8. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 1990;82:1247-59.
9. Sawin KE, Mitchison TJ. Mutations in the kinesin-like protein Eg5 disrupting localization to the mitotic spindle. Proc Natl Acad Sci U S A 1995;92:4289-93.
10. Sakowicz R, Finer JT, Beraud C, et al. Antitumor activity of a kinesin inhibitor. Cancer Res 2004;64:3276-80.
11. Marcus AI, Peters U, Thomas SL, et al. Mitotic kinesin inhibitors induce mitotic arrest and cell death in Taxol-resistant and -sensitive cancer cells. J Biol Chem 2005;280:11569-77. (Pubitemid 40418469)
12. Carter BZ, Mak DH, Shi Y, et al. Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance. Cell Cycle 2006;5:2223-9.
13. Siddiqui A, Dai C, Mansoor U, Yang L, Vitharana L, Angeles A. Spiro-condensed 1,3,4-thiadiazole derivatives for inhibiting KSP kinesin activity. WO 2009/052288.
14. Sheth PR, Basso A, Duca JS, et al. Thermodynamics of nucleotide and inhibitor binding to wild-type and ispinesib-resistant forms of human kinesin spindle protein. Biochemistry 2009;48:11045-55.
15. Liu M, Aneja R, Liu C, et al. Inhibition of the mitotic kinesin Eg5 upregulates Hsp70 through the phosphatidylinositol 3-kinase/Akt pathway in multiple myeloma cells. J Biol Chem 2006;281:18090-7.
16. Davis DA, Sarkar SH, Hussain M, Li Y, Sarkar FH. Increased therapeutic potential of an experimental anti-mitotic inhibitor SB715992 by genistein in PC-3 human prostate cancer cell line. BMC Cancer 2006;6:22.
17. Hayashi N, Koller E, Fazli L, Gleave ME. Effects of Eg5 knockdown on human prostate cancer xenograft growth and chemosensitivity. Prostate 2008;68:1283-95.